1983 INDEX

A

Abdomen NMR imaging of, May 63-65 pain in chronic pancreatitis, Mar. 71

Abortion: in SLE, 1982, Oct. 53
Abscess cavity: in colonic
diverticulitis, 1982, Dec. 41–
42

Acute illness: lung disease in, diffuse interstitial, Sept. 31– 32

Adenocarcinoma: of stomach, metastatic, Sept. 41

Adenosine 3',5'-cyclic monophosphate: and prostaglandin, 1983, Dec. 17-18

AIDS, 1983, Oct. 5–48 Burkitt's lymphoma in, 1983, Oct. 33–34

cancers in, common, 1983, Oct. 28-35 candidiasis in, 1983, Oct. 22-23

chorioretinitis in, 1983, Oct. 13 clinical problems in, frequent, 1983, Oct. 9-13 clinical syndrome of, 1983, Oct.

7-35 cryptococcal infection in, 1983, Oct. 26-27

cytomegalovirus infection in, 1983, Oct. 20-22 definition, 1983, Oct. 5-7 diarrhea in, 1983, Oct. 12-13 dyspnea in, 1983, Oct. 9-10

epidemiologic data on, current, 1983, Oct. 39–41 etiology, 1983, Oct. 43–46 family members of patients, precautions for, 1983, Oct. 41–43 fever in, 1983, Oct. 10-11 health care workers in, precautions for, 1983, Oct. 41-43

herpes simplex in, 1983, Oct. 25–26

historical perspective on, 1983, Oct. 5-7

infections common in, opportunistic, 1983, Oct. 7– 28

specific infections, 1983, Oct. 13-28

infectious manifestations, common, therapy, 1983, Oct. 18–19

infectious processes in, common, 1983, Oct. 14

Kaposi's sarcoma in, 1983, Oct. 28-33

laboratory evaluation, 1983, Oct. 35-41

lymphadenopathy in, persistent generalized, 1983, Oct. 34– 35

mycobacteria in, 1983, Oct. 23-25

neurologic dysfunction in, 1983, Oct. 11-12_

pneumonia in, Pneumocystis, 1983, Oct. 15–20

prodrome, 1983, Oct. 7-9 pulmonary infiltrates in, 1983, Oct. 9-10

toxoplasmosis in, 1983, Oct. 27– 28

treatment, 1983, Oct. 43-46

Air pollution: vitamin C preventing lung damage from, Feb. 17

Algorithms: for insulin adjustment, Apr. 28 Allergic alveolitis (see Alveolitis, extrinsic allergic) Allergic syndromes: and NSAIDs, 1983, Dec. 31 Alpha-tocopherol (see Vitamins, E) carcinoma, differential diagnosis, Sept. 30 cell carcinoma, Sept. 8 proteinosis, differential diagnosis, Sept. 29-30 Alveolitis, extrinsic allergic causes of, Sept. 25-26 diagnosis, differential, Sept. 25forms of, Sept. 25-26 Anemia: iron-deficiency, ferritin level in, Aug. 25 Aneuploidy, 1983, Nov. 6 Aneurysm aortic, echocardiography of, twodimensional, Jan. 26 ventricular, left, Jan. 35 Angioarchitecture: of colonic diverticulum, 1982, Dec. 49 Angiodysplasia: of colon, causing hemorrhage, 1982, Dec. 51 Angiography of hemorrhage from sigmoid diverticulum, 1982, Dec. 55 pulmonary, in pulmonary embolism, 1982, Nov. 17, 18 Antibody(ies) antinuclear (see Antinuclear antibodies) monoclonal, 1983, Nov. 6 production of, 1983, Nov. 18 Anticoagulants in pulmonary embolism, 1982, Nov. 19-24 long-term, 1982, Nov. 22-24 Anti-inflammatory drugs, 1983, Dec. 5-46 glossary for, 1983, Dec. 5 in lupus erythematosus,

systemic, 1983, Oct. 50-51

nonsteroidal (see NSAIDs)

19 - 24

Oct. 49-50

prostaglandin and, 1983, Dec.

Antimalarial drugs: in SLE, 1982.

Antinuclear antibodies drug-induced, management, 1982, Oct. 58 immunofluorescence of, indirect, 1982, Oct. 40-43 in SLE, 1982, Oct. 39-43 Antiplatelet agents: in pulmonary embolism, 1982, Nov. 37 Anus: canal hemorrhage, characteristics of, 1982, Dec. Aortic aneurysm, echocardiography of, two-dimensional, Jan. 26 regurgitation, Jan. 25-26 stenosis (see Stenosis, aortic) valve, Jan. 22 Aphasia: Broca's, May 48 Aplastic crisis: in sickle cell disease, July 23-24 Apolipoprotein metabolism, June 22 - 24Apoprotein A. June 24 B. June 22 C, June 23 E, June 23 Appendix: diverticula of, 1982, Dec. 32 Arteries atheromatous, cross sections of, June 17 coronary, disease, Jan. 34-42 wall response factors and atherosclerosis, June 46-47 Ascites: Walker sarcoma, pH change in, May 37 Ascorbic acid (see Vitamins, C) Aseptic necrosis: in SLE, 1982, Oct. 52-53 Aspirin in lupus erythematosus, systemic, 1982, Oct. 50-51 structure of, 1983, Dec. 23

Atherogenic mechanisms: for

Atheromatous arteries: cross

sections of, June 17

June 31-35

smoking, June 39-41 Atherogenicity: of lipoproteins. Atherosclerosis, June 3-58 arterial wall response factors and, June 46-47 chemistry of lesions, June 7-9 cholesterol and, June 24-26 chylomicrons and, June 21 collagen deposition in, June 16diabetes and, June 41-42 documented hypertension and, June 36 smoking and, June 39 early lesions, June 7 fatty acids and, saturated, June 45 - 46fatty streaks in. June 6 foam cell formation in. June 18hemodynamic factors in, June 37 - 38hypertension and, June 35-38 "intermediate" lesions in, June 9 lipids and, June 26-28 lipoproteins and, June 20-35 mechanisms of, and hypertension, June 37-38 niacin preventing or reversing, Feb. 25-27 obesity and, June 43-44 pathology gross, June 4-5 microscopic, June 6-7 plaques atheromatous, lipoproteins in, June 9 circulating factors in, June 11 - 12endothelial barrier and, June endothelial injury in, June 10 - 12evolution, June 9-19 fibrous, June 7, 8 hemodynamic stresses and, June 11 lipid infiltration in, plasma, June 13-16 smooth muscle cell proliferation and, June 12

risk factors for, June 19-35

ct,

ry

ec.

f,

e

f.

47

1

secondary, June 42-46 salt and, dietary, June 46 smoking and, June 38-41 smoking as risk factor, June vasa vasorum in, role of, June 13 - 16vitamin C preventing, Feb. 15-Athletic prowess: and vitamin E, Feb. 45 Atrial fibrillation. echophonocardiography of, Jan. 13 myxoma, Jan. 38 septal defect, ostium primum, echocardiography of, twodimensional, Jan. 45 thrombus, Jan. 16 Autosyringe model AS-6C, Apr. 35

В

Beef tallow: (in mice), 1983, Dec. Bentiromide test: in chronic pancreatitis, Mar. 59-61 Beta^s gene: restriction site polymorphism linked to, July 64 Binswanger's disease, May 47 Biology (see Molecular biology) Biomedical technology: and cancer, 1983, Nov. 32-38 Biopsy kidney, in SLE, 1982, Oct. 23in lung disease, diffuse interstitial, Sept. 33-36 procedures, Sept. 33-36 studies in insulin-dependent diabetes, Apr. 11-13 Biotin, Feb. 31 untoward effects, Feb. 31 Bleeding (see Hemorrhage) Bowel: small, in pseudocyst of pancreas, Mar. 38 **Prain**

imaging

Brain (cont.)

in lupus erythematosus, systemic, 1982, Oct. 29 - 30

NMR (see Nuclear magnetic resonance, imaging, of brain)

tumors, NMR imaging of, May 49 - 51

Breast disease: fibrocystic, and vitamin E, Feb. 41 Broca's aphasia, May 48 Burkitt's lymphoma: in AIDS, 1983, Oct. 33-34

Cadmium: and smoking, June 40 Calcification of pancreas (see Pancreas, calcification)

in AIDS, common cancers, 1983, Oct. 28-35

biomedical technology and, 1983, Nov. 32-38

metastatic, differential diagnosis, Sept. 31 vitamin megadoses in, Feb. 48-

Candidiasis: in AIDS, 1983, Oct. 22 - 23

Carbon monoxide: and smoking, June 40

Carcinoma

adenocarcinoma of stomach, metastatic, Sept. 41 alveolar cell, Sept. 8 alveolar, differential diagnosis,

Sept. 30 sigmoid colon, 1982, Dec. 44

Cardiac (see Heart) Cardiomyopathy, Jan. 29-32 congestive, ventricular thrombus in, Jan. 39

Care (see Health care) CAT scanning: in SLE, 1982, Oct. 29 - 30

CCK test: in chronic pancreatitis, Mar. 57

cDNA, 1983, Nov. 6

Cecal diverticulum: solitary, 1982, Dec. 36-37

Cell(s)

alveolar cell carcinoma, Sept. 8 eukaryotic, 1983, Nov. 6 foam cell formation in

atherosclerosis, June 18-19 giant cell tumor of radius, NMR images of, May 34

human, growth in tissue culture, 1983, Nov. 9-11

100-cell differential count. variability of, Aug. 14 sickle cell (see Sickle cell) single cell plating, 1983, Nov. 7 smooth muscle cell proliferation

in atherosclerosis, June 12 somatic (see Hybrids, somatic cell)

Central nervous system: and NSAIDs, 1983, Dec. 30-31

Cerebrospinal fluid abnormalities: in SLE, 1982, Oct. 29 Chest

NMR imaging of, May 63-65 radiography, in lung disease, Sept. 7-10

Children: SLE of, 1982, Oct. 60-61 Cholangiography: of pancreatic calcification and stenosis, Mar. 54

Cholangiopancreatography of pancreatic calcification, Mar.

of pancreatic duct stone, Mar. 45 in pancreatitis, chronic, Mar. 62 - 66

Cholecystokinin test: in chronic pancreatitis, Mar. 57

Cholesterol absorption, June 24 atherosclerosis and, June 24-26 catabolism, June 24-25 dietary, June 24, 44-45 HDL, and vitamin E, Feb. 43

level and coronary events, June metabolism, June 24-26 plasma, June 25

total, June 26-28

, 1982,

lept. 8

, NMR culture,

Nov. 7 eration ne 12 atic

d 0–31 alities:

60-61 atic

-65

Mar. Iar. 45

lar. onic

24–26

43 June reverse transport, June 25–26 synthesis, June 24–25

Chorioretinitis: in AIDS, 1983, Oct. 13

Chromosomes

identification of, 1983, Nov. 11-14

recombinant DNA techniques and, 1983, Nov. 28–29 study of, 1983, Nov. 11–14 Chylomicrons, June 32–33 atherosclerosis and, June 21 remnants of, June 32–33

Claudication: and vitamin E, Feb. 42–43

Cloning vectors, 1983, Nov. 6 Collagen: deposition in atherosclerosis, June 16-18

Colon

angiodysplasia, causing hemorrhage, 1982, Dec. 51 diverticula (see Diverticula, colon)

diverticulitis (see Diverticulitis, colon)

diverticulosis (see Diverticulosis, colon)

sigmoid (see Sigmoid)
Complement abnormalities: in
SLE, 1982, Oct. 37–39

Computed (see Tomography, computed)

Connective tissue: mixed connective tissue disease in SLE, 1982, Oct. 60

Contraceptives: oral, and vitamin B₆, Feb. 28–29

Coronary

artery disease, Jan. 34–42 events, and cholesterol level, June 27

Corticosteroids

in lupus erythematosus, systemic, 1982, Oct. 48–49 prostaglandin and, 1983, Dec. 32–33

Costs: health care costs, Aug. 9 Coumadin: in pulmonary embolism, 1982, Nov. 34 Cramps: of leg and foot, vitamin E, Feb. 44

Cryptococcal infection: in AIDS, 1983, Oct. 26–27

Cytomegalovirus infection: in AIDS, 1983, Oct. 20-22

D

Death: sudden infant death syndrome prevented by vitamin C, Feb. 17-18

Deletion mutant, 1983, Nov. 6 Diabetes mellitus

atherosclerosis and, June 41–42

complications prevented or delayed by vitamin C, Feb. 16-17

insulin-dependent, Apr. 8-65 animal models in, studies of, Apr. 19-20 biopsy studies in, Apr. 11-13

control approaches, Apr. 11-13 control approaches, Apr. 8-65 insulin pumps in (see Insulin, pumps) intensive ambulatory

treatment (see below) metabolic studies in, Apr. 13-

self-monitoring in (see Selfmonitoring)

transplant of pancreas and islets in, Apr. 52–57 treatment response in, Apr. 17–19

insulin-dependent, intensive ambulatory treatment, Apr. 20-48

economic impact, Apr. 44–45 impact on complications, Apr. 43–44

indications, Apr. 46–48 long-term, contraindications, Apr. 47

recommendations, Apr. 46–48 short-term benefit from, Apr. 48

normal metabolism in, rationale for restoring, Apr. 10-20

Diarrhea, Mar. 60 Meckel's diverticulum, 1982, in AIDS, 1983, Oct. 12-13 Dec. 28-30 Distribution: Gaussian frequency, diagnosis, 1982, Dec. 30 scanning with 99mTc-Aug. 17 Diverticula, 1982, Dec. 5-61 pertechnetate, 1982, Dec. 31 appendix, 1982, Dec. 32 pharyngeal, 1982, Dec. 7 cecum, solitary diverticulum, sigmoid 1982, Dec. 36-37 giant, 1982, Dec. 37 colon, 1982, Dec. 32-57 hemorrhage (see Hemorrhage, angioarchitecture of, 1982, in diverticulum of sigmoid) Dec. 49 stomach, 1982, Dec. 15-19 epidemiology, 1982, Dec. 33 juxtacardiac, 1982, Dec. 19 formation of, 1982, Dec. 36 Zenker's diverticulum, 1982, hemorrhage in, 1982, Dec. 47-Dec. 7-11 57 Diverticulitis, colon, 1982, Dec. multiple, 1982, Dec. 34 41 - 46pathology, 1982, Dec. 33-35 abscess cavity in, Dec. 1982, 41duodenum, 1982, Dec. 19-25 clinical manifestations, 1982, clinical picture, Dec. 1982, 41-Dec. 21-22 43 complications, 1982, Dec. 23sigmoid, 1982, Dec. 44 treatment, 1982, Dec. 46-47 radiography of, 1982, Dec. 22-Diverticulosis colon treatment, 1982, Dec. 24-25 clinical features, 1982, Dec. esophagus, Dec. 11-15 39 - 40epiphrenic, 1982, Dec. 15, 16 complications, 1982, Dec. 41midesophageal traction, 1982, Dec. 13 hemorrhage of (see multiple, 1982, Dec. 14 Hemorrhage, in scleroderma and, 1982, Dec. 15 diverticulosis of colon) subdiaphragmatic, 1982, Dec. pathogenesis, 1982, Dec. 37-14 upper, 1982, Dec. 12 right-sided, 1982, Dec. 35-36 gastrointestinal, 1982, Dec. 5-61 ileum, 1982, Dec. 25-28 hypopharyngeal intestine, small, steatorrhea in, anterior, 1982, Dec. 6-7 1982, Dec. 27 lateral, Dec. 1982, 6-7 jejunum, 1982, Dec. 25-28 posterior, Dec. 1982, 7-11 sigmoid, 1982, Dec. 43 ileum, terminal, 1982, Dec. 30spastic, management, 1982, Dec. 31 40-41 interaorticobronchial, 1982, Dec. DNA 12 cloning, 1983, Nov. 25 interbronchial, 1982, Dec. 12-13 double-stranded, 1983, Nov. 20 intestine, small probe, 1983, Nov. 6 clinical manifestations, 1982, recombinant (see Recombinant Dec. 27-28 DNA) complications, 1982, Dec. 27reiterated sequence, 1983, Nov.

restriction and, 1983, Nov. 7

Do

D

multiple, 1982, Dec. 26

unique sequence, 1983, Nov. 7 promoter region, 1983, Nov. 36 terminator region, 1983, Nov. Doppler flow detection: in deep vein thrombosis, 1982, Nov. Drug(s) anti-inflammatory (see Antiinflammatory drugs) antimalarial, in SLE, 1982, Oct. 49 - 50antiplatelet, in pulmonary embolism, 1982, Nov. 37 induced antinuclear antibodies 1983, Oct. 58 -induced lupus (see Lupus, druginduced) lung disease due to, diffuse interstitial, Sept. 30 in lung disease etiology, diffuse interstitial, Sept. 12 thrombolytic (see Embolism. pulmonary, thrombolytic agents) vasoactive, in pulmonary embolism, 1982, Nov. 37 Duodenum (see Diverticula, duodenum) D-xylose test: in chronic pancreatitis, Mar. 59, 60

ec. 31

hage,

noid)

19

2,

ec.

2, 41-

41-

ec.

41-

37-

-36

in,

Dec.

20

nt

ov.

Dyspnea: in AIDS, 1983, *Oct.* 9–10

Dysbetalipoproteinemia: familial,

June 30-31

Echocardiography, Jan. 6-53 of mitral regurgitation, Jan. 18 of mitral stenosis, Jan. 11 of mitral valve, normal, Jan. 11 M-mode in aortic stenosis, Jan. 23 in aortic stenosis, subvalvular, Jan. 24 in IHSS, Jan. 31 in mitral prolapse, Jan. 19 of mitral stenosis, Jan. 16 normal, Jan. 8

in pericardial effusion, Jan. 43 new developments in, Jan. 47overview of, Jan. 47-49 two-dimensional in aortic aneurysm, Jan. 26 in atrial septal defect, ostium primum, Jan. 45 in mitral endocarditis, Jan. 40, 41 normal, Jan. 8-9 Echophonocardiography: of atrial fibrillation, Jan. 13 Ectasias: of pancreatic duct, Mar. 63, 64 Electrocardiography: in pulmonary embolism, 1982, Nov. 15 Electroencephalography: in SLE, 1982, Oct. 29 Embolectomy: pulmonary, in embolism, 1982, Nov. 29-30 Embolism, pulmonary, 1982, Nov. 4-41 adjunctive therapy, 1982, Nov. angiography of, pulmonary, 1982, Nov. 17-18 anticoagulants in, 1982, Nov. 19 - 24long-term, 1982, Nov. 22-24 antiplatelet agents in, 1982, Nov. 37 coumadin in, 1982, Nov. 34 diagnosis, 1982, Nov. 13-19 methods, 1982, Nov. 14 electrocardiography of, 1982, Nov. 15 embolectomy in, pulmonary, 1982, Nov. 29-30 epidemiology, 1982, Nov. 4-6 evaluation for, 1982, Nov. 19 heparin in, 1982, Nov. 34-37 lytic therapy, clinical considerations with, 1982, Nov. 26 pathophysiology of, 1982, Nov. prevention by interrupting

venous system, 1982, Nov.

30 - 32

Embolism (cont.) prophylaxis, 1982, Nov. 33-38 Fat: stool, in chronic pancreatitis, physical, 1982, Nov. 37-38 Mar. 58 scanning of, perfusion and Fatty acid ventilation, 1982, Nov. 15polyunsaturated precursors, 1983, Dec. 14 signs of, 1982, Nov. 12-13 substrates, in prostaglandin streptokinase in, 1982, Nov. 25 and leukotriene synthesis, study of deep venous system of 1983, Dec. 35 legs in, 1982, Nov. 17-18 saturated, and atherosclerosis, surgery of, 1982, Nov. 29-32 June 45-46 symptoms of, 1982, Nov. 12-13 Fatty streaks: in atherosclerosis, presenting, 1982, Nov. 13 June 6 thrombolytic agents in, 1982, Ferritin level: in iron-deficiency Nov. 24-29 anemia, Aug. 25 contraindications, 1982, Nov. Fever: in AIDS, 1983, Oct. 10-11 Fibrillation: atrial, results, 1982, Nov. 26 echophonocardiography of, urokinase in, 1982, Nov. 25 Jan. 13 vasoactive drugs in, 1982, Nov. Fibrinogen: 125I-, scanning in deep vein thrombosis, 1982, Nov. Encephalopathy: hypertensive subcortical, May 47 Fibroblasts: tissue culture of, 1983, Endocarditis: mitral. Nov. 10 echocardiography in, two-Fibrosis-pneumonitis: classic dimensional, Jan. 40, 41 interstitial, differential Endonucleases: restriction, 1983, diagnosis, Sept. 19-21 Nov. 7 Foam cell formation: and Endothelial atherosclerosis, June 18-19 barrier, and atherosclerosis, Folic acid, Feb. 29-30 June 13 untoward effects, Feb. 30 injury, and plaque in atherosclerosis, June 10-12 Enzyme: restriction, recognition site for, 1983, Nov. 22 ERCP (see Cholangiopancreatography) Esophagus diverticula (see Diverticula, esophagus)

pseudodiverticulosis, intramural,

1982, Dec. 13-14 Eukaryotic cells, 1983, Nov. 6

Extremities: NMR imaging of,

Eye manifestations: of SLE, 1982,

Examination (see Physical examination)

May 63

Oct. 33

Foot cramps: vitamin E in, Feb. 44 Frequency distribution: Gaussian, Aug. 17 G Gastric (see Stomach) Gastrointestinal diverticula, 1982, Dec. 5-61 manifestations of SLE, 1982, Oct. 31-33 toxicity of NSAIDs, 1983, Dec. Gaussian frequency distribution, Aug. 17

β*, restriction site polymorphism linked to, July 64

eatitis, indin hesis, rosis, rosis, ency 10 - 11hy of, in deep 2, Nov. of, 1983, ic ial

1 18 - 19Feb. 44 ussian,

-61

Dec. ution,

982,

orphism

globin (see Globin gene) recombinant DNA techniques and, 1983, Nov. 28-29

Genetics: of α -thalassemia, July 39 - 41Genotypic attributes: of somatic

cell hybrids, 1983, Nov. 16 Giant cell tumor: of radius, NMR

images of, May 34 Glioma: NMR imaging of, May 50-51

Globin chain synthesis: switches in, July 11

Globin gene clusters, July 10 expression defects, July 37-59 organization, July 10-12 transfer of genetic information to globin protein product, July 38

Globin protein product, July 38 Glossary: for molecular biology, 1983, Nov. 6-7

Glucocorticoid inhibition: of prostaglandin and leukotriene synthesis, 1983, Dec. 34

Glucose response to portable insulin pump, Apr. 37 self-monitoring (see Selfmonitoring of glucose) Glycosylated hemoglobin: total,

and portable insulin pump, Apr. 38

factors, Feb. 11 of human cells in tissue culture, 1983, Nov. 9-11

Hb (see Hemoglobin) Headaches: in SLE, 1982, Oct. 28-Healing: wound, and vitamin C. Feb. 18-19 Health care

costs, Aug. 9

workers, precautions for, in AIDS, 1983, Oct. 41-43

Heart disease

congenital, Jan. 44-47 ischemic, and vitamin E. Feb. 41 - 42

valvular, Jan. 11-29 failure, congestive

diagnosis, differential, Sept. 32 - 33

after treatment, Sept. 45 before treatment, Sept. 44 manifestations of SLE, 1982, Oct. 26-27

masses, Jan. 37-42 NMR imaging (see Nuclear magnetic resonance, imaging, of heart)

Heinz bodies, July 33 Hematologic abnormalities: in SLE, 1982, Oct. 34-35 Hemoglobin

A, conversion to hemoglobin A_{1C}, Apr. 15 composition of, July 12 disease, unstable, July 32-36 function, July 7-9 glycosylated, total, and portable insulin pump, Apr. 38

H disease, July 43-46 M, July 31-32 migration pattern of, July 20 oxygen affinity altered in, July 36 - 37reference limits for, Aug. 19

structure, July 7-9 Hemoglobinopathy, July 7-74

prenatal diagnosis of, July 59structural, July 13-37 Hemorrhage

of anal canal, characteristics of, 1982, Dec. 52 in angiodysplasia of colon, characteristics, 1982, Dec.

in diverticula of colon, 1982, Dec. 47-57

Hemorrhage (cont.) in diverticulosis of colon characteristics of, 1982, Dec. pathogenesis of, 1982, Dec. 50 in diverticulum of sigmoid angiography in, 1982, Dec. 55 Pitressin in, 1982, Dec. 56 rectum, gross, 1982, Dec. 48 clinical points regarding, 1982, Dec. 54 work-up, 1982, Dec. 53 Hemostasis: and thrombosis prevention, 1983, Dec. 27-Heparin: in pulmonary embolism, 1982, Nov. 19-21, 34-37 Herpes simplex: in AIDS, 1983, Oct. 25-26 12-HETE, 1983, Dec. 11 Histiocytosis X cases, Sept. 43 diagnosis, differential, Sept. 28radiography of, honeycombing in, Sept. 9 Histoplasmosis: disseminated, cases, Sept. 49 Home-monitoring systems: properties of, Apr. 24-25 Honeycombing: of radiography in histiocytosis X, Sept. 9 12-HPETE: formation, 1983, Dec. Hybrid(s), somatic cell, 1983, Nov. 7.14 - 19genotypic attributes of, 1983, Nov. 16 production of, 1983, Nov. 15

Hybridization: in situ, 1983, Nov.

12-Hydroperoxyeicosatetraenoic acid: formation, 1983, Dec.

Hydrops: α-thalassemia, July 46-

12-Hydroxyeicosatetraenoic acid,

1983, Dec. 11

Hybridoma, 1983, Nov. 6

Hyperamylasemia: causes of, Mar. Hyperamylasuria: causes of, Mar. Hyperbilirubinemia: in acute pancreatitis, Mar. 21 Hypercholesterolemia, familial, June 28-29 lipoprotein pathways in, June 29 Hypercholesterolemia, polygenic, June 31 lipoprotein pathways in, June 31 Hyperglycemia: in acute pancreatitis, Mar. 20-21 Hyperlipidemia familial combined, June 29-30 lipoprotein pathways in, June 30 genetic, June 28-31 Hypertension atherosclerosis and, June 35-38 established, June 35 mild, borderline, June 35-36 as risk factor in atherosclerosis, June 35-36 Hypertriglyceridemia: familial, June 30 Hypoglycemia: nocturnal, and portable insulin pumps, Apr. Hypopharyngeal (see Diverticula, hypopharyngeal) Ideotype, 1983, Nov. 6 normal human, 1983, Nov. 13 IHSS: echocardiography of, Mmode, Jan. 31

gi

Imr

Imn

Imp

Infa

Infa

m

w

ad

-de

inj

pu

pu

pu

p

tre

Intest

(Se

ma

sma

d

Insu

mode, Jan. 31

Ileum diverticulosis, 1982, Dec. 25–28 terminal, diverticula of, 1982, Dec. 30–31

Imaging (see Scanning)

Immunodeficiency syndrome, acquired (see AIDS)

Immunofluorescence indirect, of antinuclear antibodies, 1982, Oct. 40–43

studies in SLE, 1982, Oct. 43 Immunoreactivity: trypsin-like, in chronic pancreatitis, Mar. 61

Immunosuppression: in diffuse interstitial lung disease, Sept. 31–32

Implantable pumps: in insulindependent diabetes, Apr. 49-52

Infant: sudden infant death syndrome prevented by vitamin C, Feb. 17-18

1

or.

8

43

Infarction multiple infarctions, May 46 watershed, May 45 Insulin

adjustment, algorithms for, Apr. 28

-dependent diabetes (see Diabetes mellitus, insulindependent)

injection, self-monitoring (see Self-monitoring of glucose and insulin injections) pumps, closed-loop, Apr. 49-52 pumps, implantable, Apr. 49-52

pumps, portable, Apr. 30–43 adverse effects, Apr. 41–43 characteristics of, Apr. 32–33 equipment for, Apr. 31–36 glucose response to, Apr. 37 hemoglobin with, total

glycosylated, Apr. 38 hypoglycemia in, nocturnal, Apr. 36 vs. manual injection, Apr. 45

procedures, Apr. 31–36 treatment response in, Apr. 36–

Intestine

(See also Gastrointestinal) manifestations of SLE, 1982, Oct. 31–33

small

diverticula (see Diverticula, intestine, small) diverticulosis, steatorrhea in, 1982, Dec. 27 Iodine-125-fibrinogen scanning: of deep vein thrombosis, 1982, Nov. 9-10

Iron

chelation in β-thalassemia, July 57–59

-deficiency anemia, ferritin level in, Aug. 25

overload, in beta-thalassemia, July 55-56

Ischemic insult: myocardial, NMR imaging of, May 59-61

Islet transplant (see Transplantation, islet)

Isotopes: NMR data on, May 13

J

Jejunum: diverticulosis, 1982, Dec. 25-28 Joints: in SLE, 1982, Oct. 11-13

K

Kaposi's sarcoma: in AIDS, 1983, Oct. 28-33 Karyotype: idealized, 1983, Nov.

Vidnov.

Kidney disease (see Lupus erythematosus, systemic, with kidney disease) toxicity of NSAIDs, 1983, Dec.

tubular abnormalities in SLE, 1982, Oct. 23

Kilobase, 1983, Nov. 6

L

Laboratory tests, Aug. 7–41
abnormal results, and more
tests, Aug. 21–22
abnormal tests, fallacy of, Aug.
11
accuracy of, Aug. 12–14
calculation, Aug. 27–28
completeness of, fallacy of, Aug.
11–12

Laboratory tests (cont.) criteria general, for good test, Aug. for judging, Aug. 35 diagnostic tests guidelines for, Aug. 39 multiple tests, Aug. 29-34 sequential tests, Aug. 32-34 simultaneous tests, Aug. 29-32 single tests, Aug. 28-29 strategies in, Aug. 28-34 efficiency of, Aug. 14-16 follow-up tests, guidelines for, Aug. 39 future developments in, Aug. 38 hypothetical test, frequency distributions for, Aug. 21 "normal," definition of, Aug. 16-17 100-cell differential count. variability of, Aug. 14 ordering, reasons for, Aug. 9-12 performance, measures of, Aug. 12 - 26precision of, Aug. 12-14 predictive value, Aug. 22–26 reference range, definition of, Aug. 17-21 results, expected, Aug. 15 screening test, Aug. 15-16 sensitivity of, Aug. 14-16 specificity of, Aug. 14-16 "stat" tests, Aug. 36-37 tests under development, Aug. unclassifiable disease states and, Aug. 37-38 volume of, Aug. 8 Lactoferrin: in chronic pancreatitis, Mar. 62 Laparotomy: in acute pancreatitis, Mar. 33 Leg

cramps, vitamin E in, Feb. 44 deep venous system of, in

Nov. 17-18

pulmonary embolism, 1982,

Leukocyte counts: frequency distribution of, Aug. 20 Leukocytosis: in acute pancreatitis, Mar. 20 Leukotriene biochemistry, 1983, Dec. 11-14 biosynthesis, 1983, Dec. 13 functions of, 1983, Dec. 15-18 structure, 1983, Dec. 13 synthesis fatty acid substrates in, 1983, Dec. 35 glucocorticoids inhibiting, 1983, Dec. 34 Lipase: in pancreatic extract preparations, Mar. 73 Lipid(s) atherosclerosis and, June 26-28 infiltration, plasma, in atherosclerosis, June 13-16 vitamin A and, Feb. 34-35 Lipoproteins apolipoprotein metabolism, June 22 - 24atherogenicity of, June 31-35 in atheromatous plaque, June 9 atherosclerosis and, June 20-35 HDL, June 22, 34 LDL, June 22, 34 metabolism of, June 20-22 pathways in hypercholesterolemia, June in hypercholesterolemia, polygenic, June 31 in hyperlipidemia, June 30 production, increased, June 34smoking and, June 40 vitamin E and, Feb. 43 VLDL, June 21-22, 33 remnants of, June 33-34 Lipoxygenase, 1983, Dec. 34 12-Lipoxygenase products: formation of, 1983, Dec. 11 Liver toxicity: and NSAIDs, 1983, Dec. 32 Lundh test meal: in chronic

pancreatitis, Mar. 58

I

Lung (See also Pulmonary) damage from smoking or air pollution prevented by vitamin C. Feb. 17 disease, diffuse interstitial, Sept. 5 - 56in acute illness, Sept. 31-32 biopsy in, Sept. 33-36 biopsy in, procedures, Sept. 33-36 83. cases, Sept. 38-39 diagnosis, clues to, Sept. 51 - 53diagnosis, differential, Sept. 18 - 33drug-induced, Sept. 30 -28 etiology, drugs implicated in, Sept. 12 history, Sept. 11-13 -16 after immunosuppression, Sept. 31-32 lung function studies in, Sept. une physical examination in, Sept. 13 - 14e 9 radiography in, chest, Sept. -357 - 10therapy, Sept. 36-38 tissue processing in, Sept. 36 function studies in diffuse interstitial lung disease, lune Sept. 14-18 infiltrates in AIDS, 1983, Oct. 9 - 10manifestations of SLE, 1982, Oct. 25-26 34nitrofurantoin lung reaction, Sept. 47 Lupus discoid, 1982, Oct. 53-55 drug-induced, 1982, Oct. 55-59 clinical features, 1982, Oct.

56 - 57

course of, 1982, Oct. 57-58

management, 1982, Oct. 58

erythematosus (see below)

laboratory features, 1982, Oct.

14

5

0

. 11

983.

nephritis (see Nephritis, lupus) subsets, 1982, Oct. 53-59 Lupus erythematosus, systemic, 1982, Oct. 8-82 abortion and, 1982, Oct. 53 anti-inflammatory drugs in, 1982, Oct. 50-51 antimalarial drugs in, 1982, Oct. 49-50 antinuclear antibodies in, 1982, Oct. 39-43 aspirin in, 1982, Oct. 50-51 cerebrospinal fluid abnormalities and, 1982, Oct. 29 in children, 1982, Oct. 60-61 classification, 1982, Oct. 46 complement abnormalities in. 1982, Oct. 37-39 corticosteroids in, 1982, Oct. 48 - 49diagnosis, 1982, Oct. 43-47 electroencephalography in, 1982, Oct. 29 epidemiology, 1982, Oct. 9 etiology, 1982, Oct. 9-10 gastrointestinal manifestations, 1982, Oct. 31-33 headaches and, 1982, Oct. 28-29 heart manifestations, 1982, Oct. 26 - 27hematologic abnormalities in. 1982, Oct. 34-35 immunofluorescence studies in, 1982, Oct. 43 infections and, 1982, Oct. 51-52 joint manifestations, 1982, Oct. 11 - 13with kidney disease, 1982, Oct. 18 - 25biopsy of kidney in, 1982, Oct. 23 - 24interstitial abnormalities in, 1982, Oct. 23 pathologic findings in, 1982, Oct. 19-20 prognosis, 1982, Oct. 25 treatment, 1982, Oct. 24-25 tubular abnormalities in, 1982, Oct. 23

Lupus erythematosus (cont.) laboratory abnormalities in. 1982, Oct. 35-39 lymphadenopathy in, 1982, Oct. 30 - 31management, 1982, Oct. 47-51 by organ system, 1982, Oct. 50 manifestations, 14, incidence of, 1982, Oct. 44-45 mixed connective tissue disease and, 1982, Oct. 60 myalgia in, 1982, Oct. 13 myositis in, 1982, Oct. 13 necrosis in, aseptic, 1982, Oct. neuropsychiatric manifestations, 1982, Oct. 27-30 Magnetic field: uniform, in NMR, ocular manifestations of, 1982, Oct. 33 paralysis and, 1982, Oct. 29 pathogenesis, 1982, Oct. 9-10 peripheral nervous system in, 1982, Oct. 30 pleuropulmonary manifestations, 1982, Oct. 25-26 pregnancy during, 1982, Oct. 53 psychosis and, 1982, Oct. 28 rashes in, 1982, Oct. 13-18 sun-sensitive, 1982, Oct. 17-18 scanning in brain, 1982, Oct. 29-30 CAT, 1982, Oct. 29-30 seizures and, 1982, Oct. 28 signs, general, 1982, Oct. 10-11 skin manifestations of, 1982, Oct. 13-18 therapy, 1982, Oct. 51 splenomegaly in, 1982, Oct. 30sun exposure in, 1982, Oct. 51 symptoms, general, 1982, Oct. 10 - 11tests in, routine, 1982, Oct. 47 therapy, experimental forms, 1982, Oct. 49 vascular manifestations of, 1982,

Lymphadenopathy persistent generalized, in AIDS, 1983, Oct. 34-35 in lupus ervthematosus, systemic, 1982, Oct. 30-31 Lymphangiomyomatosis: differential diagnosis, Sept. Lymphoma: Burkitt's, in AIDS, 1983, Oct. 33-34 Lyonization, 1983, Nov. 6 Lytic therapy: clinical considerations in, 1982, Nov.

M

M

M

M

M

M

Mi

My

My

My

My

My

Na

Ne

Ne

Nei fe

n

n

m

m

p

M

May 11, 18

Malignancy (see Cancer) Meckel's diverticula (see Diverticula, Meckel's diverticulum) Medical diagnosis: and recombinant DNA technology, 1983, Nov. 29-Megavitamins (see Vitamins) Menhaden oil: (in mice), 1983, Dec.

Mental alertness and function, and vitamin C, Feb. 19-20 illness, and megadoses of vitamins, Feb. 47-48 Metastases of cancer, differential diagnosis, Sept. 31 of stomach adenocarcinoma, Sept. 41

echocardiography, normal, Jan. endocarditis, echocardiography in, two-dimensional, Jan.

40, 41 prolapse, echocardiography of, M-mode, Jan. 19 regurgitation, Jan. 17-21 echocardiography of, Jan. 18

Oct. 33-34

work-up in, 1982, Oct. 48

stenosis, Jan. 12-16 echocardiography of, Jan. 11 echocardiography of, M-mode, valve, Jan. 11-12 M-mode (see Echocardiography, Mmode) Models: animal, studies in insulindependent diabetes, Apr. 19 - 20Molecular biology, 1983, Nov. 6 - 41glossary for, Nov. 1983, 6-7 survival curve, 1983, Nov. 7 Monitoring home-monitoring systems, properties of, Apr. 24-25 self-monitoring (see Selfmonitoring) Monoclonal antibody, 1983, Nov. 6 production of, 1983, Nov. 18 Muscle: smooth, cell proliferation in atherosclerosis, June 12 Mutant: deletion, 1983, Nov. 6 Myalgia: in SLE, 1982, Oct. 13 Mycobacteria: in AIDS, 1983, Oct. 23 - 25Myocardium: ischemic insult, proton NMR imaging of, May 59-61 Myositis: in SLE, 1982, Oct. 13

DS,

-31

ept.

Nov.

MR,

29-

B, Dec.

nosis,

Jan.

aphy

an.

of,

n. 18

3,

N

Myxoma: atrial, Jan. 38

Nausea: and vitamin B₅, Feb. 28 Necrosis: aseptic, in SLE, 1982, Oct. 52–53 Neoplasia (see Tumors) Nephritis, lupus focal, 1982, Oct. 20–21 membranous, 1982, Oct. 22– 23 mesangial, 1982, Oct. 20 mild, 1982, Oct. 20–21 minimal, 1982, Oct. 20 proliferative diffuse, 1982, Oct. 21–22 severe, 1982, Oct. 21–22 Nervous system central, and NSAIDs, 1983, Dec. 30 - 31peripheral, in SLE, 1982, Oct. 30 Neurologic dysfunction: in AIDS, 1983, Oct. 11-12 Neuropsychiatric manifestations: of SLE, 1982, Oct. 27-30 Niacin, Feb. 25-27 atherosclerosis prevented or reversed by, Feb. 25-27 untoward effects, Feb. 27 Nick translation, 1983, Nov. 6 Nicotine, June 39-40 Nitrofurantoin pulmonary reaction, Sept. 47 NMR (see Nuclear magnetic resonance) "Normal": definition of, Aug. 16 - 17NSAIDs, 1983, Dec. 21 allergic syndromes and, 1983, Dec. 31 central nervous system and, 1983, Dec. 30-31 reproductive system and, 1983, Dec. 31-32 toxicity, 1983, Dec. 24-33 gastrointestinal, 1983, Dec. 24 - 25liver, 1983, Dec. 32 renal, 1983, Dec. 26 Nuclear magnetic resonance, May 8-81 applications, clinical, May 8-81 chemical shift, May 17-18 complex samples in, May 19 data on selected isotopes, May imaging of abdomen, May 63-65 of brain, May 38-55 of brain, in vascular diseases, May 44-49 of brain tumors, May 49-51 of chest, May 63-65 of extremities, May 63 of giant cell tumor of radius, May 34 of glioma, May 50-51

Nuclear magnetic resonance (cont.) hazards of, potential, May 24 of heart, May 55-63 of heart, gated proton, May 55 - 59of heart, paramagnetic agents in, May 61-62 oncologic studies in, May 30principles of, May 10-24 proton spin-density, May 42of sclerosis, multiple, May 51injury in myocardial ischemic insult, proton imaging, May 50 - 61inversion-recovery pulse sequences, May 22-23 magnetic field in, uniform, May 11, 18 physics of, basic, May 10-14 proton, and tumors, May 30-35 relaxation times, May 14-17 RF pulse application of, May 12 average, May 15 sequences, May 20-24 saturation-recovery pulse sequences, May 22-23 spatial encoding techniques, May 18-20 spectroscopy, May 24-30 proton studies in, May 24-27 terminology, glossary of, May 66 - 70Nutritional approach: to prostaglandin synthesis modification, 1983, Dec. 33-

)

Obesity: and atherosclerosis, June 43-44 Ocular manifestations: of SLE, 1982, Oct. 33 Oncogenes, 1983, Nov. 6-7, 32-38 Oncologic studies: with NMR imaging, May 30–38
100-cell differential count: variability of, Aug. 14
Oral contraceptives: and vitamin B₆, Feb. 28–29
Oxygen affinity: altered, in

hemoglobin, July 36-37 Pain: abdominal, in chronic pancreatitis, Mar. 71 Pancreas calcification, Mar. 57-58 causes of, Mar. 57 cholangiography of, Mar. 54 cholangiopancreatography of, Mar. 63 ultrasound of, Mar. 41, 66 duct ectasias of, Mar. 63, 64 stone in, cholangiopancreatography of, Mar. 45 stricture of, Mar. 63 extract preparations, lipase in, Mar. 73 insufficiency, exocrine complications, Mar. 67 etiology, Mar. 50 tests in, listing of, Mar. 55 treatment, Mar. 69-74 polypeptide in chronic pancreatitis, Mar. 62 pseudocyst (see Pseudocyst of pancreas) stenosis, cholangiography of, Mar. 54 transplant (see Transplantation,

Pancreatitis, Mar. 5–81 acute

acute
clinical features, Mar. 15–24
complications of, Mar. 24–29
course of, Mar. 24–29
diagnosis, Mar. 22–24
etiology, Mar. 8, 9–15
history, Mar. 15

Par

Par

Per

d

pancreas)

40

hyperbilirubinemia in, Mar. hyperglycemia in, Mar. 20laboratory data in, Mar. 16 - 22laparotomy in, Mar. 33 leukocytosis in, Mar. 20 pathogenesis, Mar. 6-9 physical examination in, Mar. 15 - 16radiography in, Mar. 22 survival in, factors adversely influencing, Mar. 25 treatment, Mar. 30-33 abdominal pain in, Mar. 71 bentiromide test in, Mar. 59 - 61cholangiopancreatography in, Mar. 62-66 cholecystokinin test in, Mar. clinical features, Mar. 53-66 complications, Mar. 66-69 course of, Mar. 66-69 D-xylose test in, Mar. 59, 60 etiology, Mar. 49-52 examination in, physical, Mar. 53 - 54history, Mar. 53 laboratory data, Mar. 54-66 lactoferrin in, Mar. 62 Lundh test meal in, Mar. 58 pancreatic polypeptide in, Mar. 62 pathogenesis, Mar. 6-9 Schilling test in, Mar. 58-59 secretin test in, Mar. 55-57 stool fat in, Mar. 58 tests in, listing of, Mar. 55 treatment, Mar. 69-74 trypsin-like immunoreactivity in, Mar. 61 Pantothenic acid, Feb. 30-31

untoward effects, Feb. 31

disease, Jan. 42-44

Pericardial

Paralysis: and SLE, 1982, Oct. 29

in

of,

hy

in,

of

f,

ation,

1 - 29

effusion, echocardiography of, Mmode, Jan. 43 Peripheral nervous system: in SLE, 1982, Oct. 30 pH change: in Walker sarcoma ascites, May 37 Pharyngeal diverticula, 1982, Dec. Phenotypic qualities: of parent cells, 1983, Nov. 16 Phonocardiography: in aortic stenosis, Jan. 23 Phosphocreatine: and NMR images, May 38 Physical examination in pancreatitis acute, Mar. 15-16 chronic, Mar. 53-54 Pitressin: in sigmoid diverticular hemorrhage, 1982, Dec. 56 Plaques (see Atherosclerosis, plaques in) Platelet counts, frequency distribution of, Aug. 18 hemostasis, thromboxane A2 and prostacyclin, 1983, Dec. 28 Plethysmography: impedance, in deep vein thrombosis, 1982, Nov. 9, 10 Pleuropulmonary manifestations: of SLE, 1982, Oct. 25-26 Pneumoconiosis: differential diagnosis, Sept. 28 Pneumocystis pneumonia: in AIDS, 1983, Oct. 15-20 Pneumonia: Pneumocystis, in AIDS, 1983, Oct. 15-20 Pneumonitis-fibrosis: classic interstitial, differential diagnosis, Sept. 19-21 Pollution air, vitamin C preventing lung

damage from, Feb. 17 -induced diseases, vitamin E preventing, Feb. 44 Pregnancy in sickle cell disease, July 27 during SLE, 1982, Oct. 53 63 Pregnancy (cont.) vitamin E and, Feb. 44-45 Prenatal diagnosis: of hemoglobinopathy, July 59-66 Prostacyclin: and platelet hemostasis, 1983, Dec. 28 Prostaglandin, 1983, Dec. 5-46 adenosine 3',5'-cyclic monophosphate and, 1983, Dec. 17-18 anti-inflammatory drugs and, 1983, Dec. 19-24 biochemistry, 1983, Dec. 9-11 biosynthesis of, 1983, Dec. 10 corticosteroids and, 1983, Dec. 32 - 33functions of, 1983, Dec. 15-18 glossary for, 1983, Dec. 5 history, 1983, Dec. 7-9 structure of, 1983, Dec. 10 synthesis fatty acid substrates in, 1983, Dec. 35 glucocorticoid inhibiting, 1983, Dec. 34 nutritional approach to modification of, 1983, Dec. 33 - 40Prosthetic valve, Jan. 28-29 Protein apoprotein (see Apoprotein) globin protein product, July 38 Proteinosis: alveolar, differential diagnosis, Sept. 29-30 Proton NMR, and tumors, May 30-35 spin-density image, May 42-43 studies in NMR spectroscopy, May 24-27 Pseudocyst of pancreas, Mar. 33 - 49bowel in, small, Mar. 38 clinical features, Mar. 34-35, 36 - 37complications, Mar. 44-49 course of, Mar. 44-49 CT of, Mar. 43, 44 comparison with ultrasound,

definition, Mar. 33-34 diagnosis, Mar. 43 differential, Mar. 43 etiology, Mar. 34 management, Mar. 49 radiography of, Mar. 35-43 stomach compression by, Mar. ultrasound of, Mar. 40-41 Pseudodiverticulosis: of esophagus, intramural, 1982, Dec. 13 - 14Psychiatric manifestations: of SLE, 1982, Oct. 27-30 Psychosis: in SLE, 1982, Oct. 28 Pulmonary (see also Lung) angiography, in pulmonary embolism, 1982, Nov. 17, embolectomy, in embolism, 1982, Nov. 29-30 embolism (see Embolism, pulmonary) Pulmonic valve, Jan. 27-28 Pumps (see Insulin, pumps) Pyridoxine (see Vitamins, B₆)

T

Radiofrequency pulse (see under Nuclear magnetic resonance) Radiography alveolar pattern in, due to alveolar cell carcinoma, Sept. 8 chest, in diffuse interstitial lung disease, Sept. 7-10 of diverticula, duodenal, 1982, Dec. 22-23 in histiocytosis X, honeycombing, Sept. 9 in pancreatitis, Mar. 22 of pseudocyst of pancreas, Mar. 35 - 43Radioisotopes: NMR data on, May

Radius: giant cell tumor of, NMR

images of, May 34

Sali sa Salt

RE

Re

Re

Re

I

Rei

Rej

Res

a

D

e

Ret

a

a

ch

RF

Ribe

Roe

Ret

Mar. 42

Rashes in SLE, 1982, Oct. 13-18 sun-sensitive, 1982, Oct. 17-18 Recombinant DNA in disease, for study and diagnosis, 1983, Nov. 25-32 libraries, 1983, Nov. 7 techniques to map human genes to particular chromosomes, 1983, Nov. 28-29 technology, 1983, Nov. 19-21 application to medical diagnosis, 1983, Nov. 29-32 restriction analysis and, 1983, Nov. 31 techniques of, fundamental, 1983, Nov. 21-25 Rectal hemorrhage (see Hemorrhage, rectum) Regurgitation aortic, Jan. 25-26 mitral, Jan. 17-21 echocardiography of, Jan. 18 Renal (see Kidney) Reproductive system: and NSAIDs, 1983, Dec. 31-32 Restriction analysis, and recombinant DNA technology, 1983, Nov. 31 DNA and, 1983, Nov. 7 endonucleases, 1983, Nov. 7 enzyme, recognition site for, 1983, Nov. 22 map, 1983, Nov. 7 Retinol (see Vitamins, A) Retrovirus, transforming

agus,

SLE.

28

7,

1982.

der

1,

llung

982,

Mar.

, May

NMR

8

acute, 1983, Nov. 6

Riboflavin, Feb. 25

Roentgenography (see

Radiography)

acutely, 1983, Nov. 34

chronically, 1983, Nov. 35

magnetic resonance)

untoward effects of, Feb. 25

RF pulse (see under Nuclear

Salicylate(s), 1983, Dec. 22–24 salts, structure of, 1983, Dec. 23 Salt: dietary, and atherosclerosis,

June 46 Sarcoidosis diagnosis, differential, Sept. 22 - 25stage I, cases, Sept. 38 stage II, cases, Sept. 39 Sarcoma ascites, Walker, pH changes in, May 37 Kaposi's, in AIDS, 1983, Oct. 28 - 33Scanning brain, in SLE, 1982, Oct. 29-30 CAT, in SLE, 1982, Oct. 29-30 CT (see Tomography, computed) of Meckel's diverticulum, with 99mTc-pertechnetate, 1982, Dec. 31 M-mode (see Echocardiography, M-mode) NMR (see Nuclear magnetic resonance, imaging) perfusion, in pulmonary embolism, 1982, Nov. 15 - 17in thrombosis, deep vein, with ¹²⁵I-fibrinogen, 1982, Nov. 9 - 10ventilation, in pulmonary embolism, 1982, Nov. 15-17 Schilling test: in chronic pancreatitis, Mar. 58-59 Scleroderma: and esophageal diverticula, 1982, Dec. 15 Sclerosis: multiple, NMR imaging of, May 51-52 Screening test, Aug. 15-16 Secretin test: in chronic pancreatitis, Mar. 55-57 Seizures lupus ervthematosus and. systemic, 1982, Oct. 28 vitamin B6 and, Feb. 28 Self-monitoring of glucose and insulin injections, Apr. 21 - 29clinical effects, Apr. 27-29 procedures, Apr. 21-27 properties of home-monitoring

systems, Apr. 24-25

Sickling Sigmoid Smoking

June 39-41 atherosclerosis and, June 38atherosclerosis smoking as risk factor, June 38 lipoproteins and, June 40 vitamin C preventing lung damage from, Feb. 17 Sodium warfarin: in pulmonary embolism, 1982, Nov. 34 Somatic cell (see Hybrid, somatic

Septal defect: atrial, ostium primum, echocardiography of, two-dimensional, Jan. 45 Sexual dysfunction: vitamin E reversing, Feb. 44 Sickle cell disease, July 13-31 aplastic crisis in, July 23-24 clinical presentation, July 19-21 complications acute infectious, July 21-23 chronic, July 27-30 pregnancy during, July 27 splenic sequestration in, July 24 transfusion in, July 30-31 vaso-occlusive crisis in, July 24 - 27Sickle syndromes, July 17 cellular basis of, July 17-19 molecular basis of, July 14-17 diverticula (see Diverticula, sigmoid) diverticulitis and carcinoma, 1982, Dec. 44 diverticulosis, 1982, Dec. 43 Single cell plating, 1983, Nov. 7 disease, and vitamin A, Feb. 34 manifestations of SLE, 1982, Oct. 13-18 therapy of, 1982, Oct. 51 problems, and vitamin E, Feb. 40-41 atherogenic mechanisms for,

Stool fat: in chronic pancreatitis, Mar. 58

Stress hemodynamic, and plaques in atherosclerosis, June 11

Sudden infant death syndrome: prevented by vitamin C, Feb. 17-18

Spastic diverticulosis: management, 1982, Dec. 40 - 41

Su

Su

Su

Te

α-

1

8

B-7

Th

Th

Th

Th

Th

Th

Spectroscopy, NMR, May 24-30 proton studies in, May 24-27 Spleen: sequestration in sickle cell disease, July 24

Splenomegaly: in SLE, 1982, Oct. 30--31

"Stat" tests, Aug. 36-37 Steatorrhea, Mar. 60 in small intestine diverticulosis, 1982, Dec. 27 Stenosis

aortic, Jan. 22-24 echocardiography of, M-mode, Jan. 23 phonocardiography of, Jan. 23

subvalvular, echocardiography of, M-mode, Jan. 24 mitral, Jan. 12-16 echocardiography of, Jan. 11

echocardiography of, M-mode,

pancreatic, cholangiography of, Mar. 54 Stomach

(See also Gastrointestinal) adenocarcinoma, metastatic, Sept. 41

compression by pseudocyst of pancreas, Mar. 39 diverticula, 1982, Dec. 15-19 juxtacardiac, 1982, Dec. 19 manifestations of SLE, 1982,

Oct. 31-33 Stone: in pancreatic duct, cholangiopancreatography of, Mar. 45

Streptokinase: in pulmonary embolism, 1982, Nov. 25

vitamin C and, Feb. 18

Southern analysis, 1983, Nov. 27

Southern blot, 1983, Nov. 7

Sugar phosphates: and NMR imaging, May 38

Sun

ec.

-30

27

le cell

Oct.

ulosis,

mode.

an. 23

graphy

n. 11

mode,

ny of,

ic,

t of

-19

19

82,

aphy

titis.

25

es in

me:

C,

11

exposure in SLE, 1982, Oct. 51 -sensitive rashes in SLE, 1982, Oct. 17–18

Survival curve: in molecular biology, 1983, Nov. 7

T

Technetium-99m-pertechnetate: in scan of Meckel's diverticulum, 1982, Dec. 31

Thalassemia, July 37-59 intermedia, July 57

α-Thalassemia, July 39–47 distribution in world populations, July 42

genetics of, July 39-41 hydrops, July 46-47 silent carrier, July 41

syndromes, July 40 trait, July 41–43

β-Thalassemia, July 47–59 clinical aspects, July 51–52 iron chelation in, July 57–59 iron overload in, July 55–56 molecular defects in, July 48–50

therapy, July 52–54 Thiamine, Feb. 23–25 untoward effects of, Feb. 25

Thorax (see Chest) Thrombi

in atrium, Jan. 16 ventricular, in congestive cardiomyopathy, Jan. 39

Thrombolytic agents (see Embolism, pulmonary, thrombolytic agents)

Thrombophlebitis: prevented by vitamin E, Feb. 43

Thrombosis, deep vein diagnosis, 1982, Nov. 7-11 methods, 1982, Nov. 8

Doppler flow detection in, 1982, Nov. 7

examination in, clinical, 1982, Nov. 7

pathophysiology, 1982, Nov. 6-7

plethysmography of, impedance, 1982, Nov. 9, 10

1982, Nov. 9, 10 scanning with ¹²⁵I-fibrinogen, 1982, Nov. 9–10

venography of, 1982, Nov. 10-11

Thrombosis prevention hemostasis and, 1983, Dec.

27–39 by vitamin C, Feb. 14–15

Thromboxane

A₂, and platelet hemostasis, 1983, Dec. 28

biochemistry, 1983, Dec. 9-11

Tissue culture: growth of human cells in, 1983, Nov. 9-11

Tomography, computed in lupus erythematosus,

systemic, 1982, Oct. 29-30 of pseudocyst of pancreas, Mar. 43, 44

comparison with ultrasound, Mar. 42

Toxicity

NSAID (see NSAID toxicity) of vitamin A (see Vitamins, A,

toxicity)
of vitamin D, Feb. 39

Toxoplasmosis: in AIDS, 1983, Oct. 27–28

Traction diverticula:

midesophageal, 1982, Dec.

Transfusion: in sickle cell disease, July 30-31

Transplantation

islet, Apr. 52-57 failure in, causes of, Apr. 54 types of, Apr. 53

pancreas, Apr. 52–57

failure in, causes of, Apr. 54 types of, Apr. 53

Tricuspid valve, Jan. 27-28

Trypsin-like immunoreactivity: in chronic pancreatitis, Mar.

Tuberculosis: miliary, differential diagnosis, Sept. 31

Tumors

of brain, NMR imaging of, May 49-51 Tumors (cont.) NMR and, proton, May 30-35 radius, giant cell, NMR images of, May 34

U

Ultrasonography (see Ultrasound) Ultrasound of pancreatic calcification, Mar. 41,66 of pseudocyst of pancreas, Mar.

comparison with CT, Mar. 42 Urokinase: in pulmonary embolism, 1982, Nov. 25

Valve aortic (see Aortic) disease, Jan. 11-29 mitral (see Mitral) prosthetic, Jan. 28-29 pulmonic, Jan. 27-28 tricuspid, Jan. 27-28 Vasa vasorum: in atherosclerosis

evolution, June 13-16 Vascular (see Vessels) Vasoactive drugs: in pulmonary

embolism, 1982, Nov. 37 Vaso-occlusive crisis: in sickle cell disease, July 24-27

Vein system

> deep, of legs, in pulmonary embolism, 1982, Nov. 17-

interrupting to prevent pulmonary embolism, 1982, Nov. 30-32

thrombosis (see Thrombosis, deep vein)

Venography: of deep vein thrombosis, 1982, Nov. 10-11

Ventilation scanning: in pulmonary embolism, 1982, Nov. 15-17

Ventricle function, Jan. 32-34 left, aneurysm, Jan. 35 thrombus in congestive

cardiomyopathy, Jan. 39 Vessels

brain, diseases of, NMR imaging of, May 44-49 manifestations of SLE, 1982,

Oct. 33-34 peripheral, disease, and vitamin E. Feb. 42-43

Virus(es)

cytomegalovirus infection in AIDS, 1983, Oct. 20-22 DNA (see DNA, virus)

herpes simplex in AIDS, 1983, Oct. 25-26

retrovirus (see Retrovirus) Vision: and vitamin A, Feb. 33

Vitamins, Feb. 7-56 A, Feb. 32-38

effects of, purported, Feb. 32 lipids and, Feb. 34-35

resistance to disease increased by, Feb. 33 skin disease and, Feb. 34

toxicity, Feb. 35-38 toxicity, acute, manifestations, Feb. 35

toxicity, chronic, manifestations, Feb. 36 vision and, Feb. 33

B-complex, Feb. 22-23 effects of, purported, Feb. 24 - 25

Ba. Feb. 28-29 contraceptives and, oral, Feb.

nausea and, Feb. 28 seizures and, Feb. 28 untoward effects, Feb. 29

B₁₂, Feb. 30 untoward effects, Feb. 30 C, Feb. 12-22

atherosclerosis prevented by, Feb. 15-16

diabetes complications prevented or delayed by, Feb. 16-17

effects of, purported, Feb. 12 infections prevented by, Feb. megadoses, untoward actions of, Feb. 20-22 mental alertness and function and, Feb. 19-20 stress and, Feb. 18 sudden infant death syndrome prevented by, Feb. 17-18 thrombosis prevented by, venous, Feb. 14-15 wound healing and, Feb. 18 - 19classification of, Feb. 11 D, Feb. 38-39 toxicity, Feb. 39 dietary allowances, recommended daily, Feb. 53 E, Feb. 40-46 athletic prowess and, Feb. 45 breast disease and, fibrocystic, cholesterol and, HDL, Feb. 43 claudication and, Feb. 42-43 in cramps of leg and foot, Feb. effects of, purported, Feb. 40 heart disease and, ischemic, Feb. 41-42 lipoproteins and, Feb. 43 peripheral vascular disease and, Feb. 42-43 pollution-induced diseases

prevented by, Feb. 44

aging

amin

n

2

983,

33

. 32

4

36

b.

29 30 ted by,

d by,

1, Feb.

reased

ations,

pregnancy and, Feb. 44–45 sexual dysfunction reversed by, Feb. 44 skin problems and, Feb. 40–41 thrombophlebitis prevented by, Feb. 43 untoward effects, Feb. 45 fat-soluble, Feb. 32–46 K, Feb. 46 untoward effects, Feb. 46 megadoses cancer and, Feb. 48–50 mental illness and, Feb. 47–48 nonvitamin, Feb. 51 water-soluble, Feb. 12–31

W

Walker sarcoma ascites: pH change in, May 37 Warfarin: in pulmonary embolism, 1982, Nov. 34 Weight loss, Mar. 60 Wound healing: and vitamin C, Feb. 18–19

Х

X-ray (see Radiography)

\mathbf{z}

Zenker's diverticulum, 1982, Dec. 7-11